文献速递放射性药物与辐射防护

健康食蟹猴体内SARS-CoV-2单克隆抗体sotrovimab的体内生物分布与药代动力学

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-10-28

本研究在健康食蟹猴中比较LS修饰的sotrovimab(VIR-7831)与其非LS修饰等价物VIR-7831-WT的89Zr-PET/CT生物分布至注射后14天。VIR-7831在支气管SUVmean于第6天和第10天高于VIR-7831-WT,但在肝脏低于后者;VIR-7831终末半衰期21.3±3.0天长于VIR-7831-WT的16.5±1.1天,多数组织组织:血比值无统计学差异。

要点

  • 89Zr-VIR-7831支气管SUVmean第6天3.43±0.55、第10天2.66±0.32,均高于VIR-7831-WT。
  • VIR-7831终末半衰期21.3±3.0天,VIR-7831-WT为16.5±1.1天。
  • 除肝脏外,两种抗体组织:血比值无一致差异。

核心结论

  • 半衰期延长的VIR-7831在循环中停留时间长于VIR-7831-WT,与FcRn结合增强一致。
  • 实验全程多数组织的组织:血浓度比值在两种药物间保持统计学不可区分。
  • 在支气管区域检测到更高浓度的89Zr-VIR-7831。

研究设计与样本

  • 在健康食蟹猴中比较VIR-7831与VIR-7831-WT,使用89Zr标记的PET/CT显像至注射后14天。
  • 分析所有主要器官的绝对浓度及组织:血比值,重点关注呼吸道。
  • 使用基于生理的药代动力学(PBPK)模型评估组织生物分布动力学,并从PET图像和SUV值提取影像组学特征。

主要发现

  • 89Zr-VIR-7831支气管SUVmean第6天为3.43±0.55、第10天为2.66±0.32,分别高于89Zr-VIR-7831-WT的2.59±0.38和2.15±0.18。
  • 肝脏SUVmean第6天VIR-7831为5.14±0.80、VIR-7831-WT为8.63±0.89;第10天分别为4.52±0.59和7.73±0.66;第14天分别为4.95±0.65和7.94±0.54,VIR-7831均低于VIR-7831-WT。
  • VIR-7831终末半衰期为21.3±3.0天,VIR-7831-WT为16.5±1.1天。
  • 两种抗体第3天肺:血SUVmean摄取比值均为0.25,PBPK模型预测总肺组织和间质间隙与血清比值分别为0.31和0.55。
  • 影像组学分析显示VIR-7831在肺和肝脏的PET SUV分布均值集中,提示摄取较VIR-7831-WT更均匀。

临床怎么用

  • 作者认为数据可为了解单克隆抗体的组织分布与消除动力学提供见解,并可指导未来生物药物发现工作。
  • 作者指出89Zr标记的残留化特性有助于揭示抗体分解代谢部位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sotrovimab (VIR-7831), a human IgG1κ monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain (RBD). The Fc region of VIR-7831 contains an LS modification to promote neonatal Fc receptor (FcRn)-mediated recycling and extend its serum half-life. Here, we aimed to evaluate the impact of the LS modification on tissue biodistribution, by comparing VIR-7831 to its non-LS-modified equivalent, VIR-7831-WT, in cynomolgus monkeys. METHODS: 89Zr-based PET/CT imaging of VIR-7831 and VIR-7831-WT was performed up to 14 days post injection. All major organs were analyzed for absolute concentration as well as tissue:blood ratios, with the focus on the respiratory tract, and a physiologically based pharmacokinetics (PBPK) model was used to evaluate the tissue biodistribution kinetics. Radiomics features were also extracted from the PET images and SUV values. RESULTS: SUVmean uptake in the pulmonary bronchi for 89Zr-VIR-7831 was statistically higher than for 89Zr-VIR-7831-WT at days 6 (3.43 ± 0.55 and 2.59 ± 0.38, respectively) and 10 (2.66 ± 0.32 and 2.15 ± 0.18, respectively), while the reverse was observed in the liver at days 6 (5.14 ± 0.80 and 8.63 ± 0.89, respectively), 10 (4.52 ± 0.59 and 7.73 ± 0.66, respectively), and 14 (4.95 ± 0.65 and 7.94 ± 0.54, respectively). Though the calculated terminal half-life was 21.3 ± 3.0 days for VIR-7831 and 16.5 ± 1.1 days for VIR-7831-WT, no consistent differences were observed in the tissue:blood ratios between the antibodies except in the liver. While the lung:blood SUVmean uptake ratio for both mAbs was 0.25 on day 3, the PBPK model predicted the total lung tissue and the interstitial space to serum ratio to be 0.31 and 0.55, respectively. Radiomics analysis showed VIR-7831 had mean-centralized PET SUV distribution in the lung and liver, indicating more uniform uptake than VIR-7831-WT. CONCLUSION: The half-life extended VIR-7831 remained in circulation longer than VIR-7831-WT, consistent with enhanced FcRn binding, while the tissue:blood concentration ratios in most tissues for both drugs remained statistically indistinguishable throughout the course of the experiment. In the bronchiolar region, a higher concentration of 89Zr-VIR-7831 was detected. The data also allow unparalleled insight into tissue distribution and elimination kinetics of mAbs that can guide future biologic drug discovery efforts, while the residualizing nature of the 89Zr label sheds light on the sites of antibody catabolism.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Aweda TA, Cheng SH, Lenhard SC, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022. PMID: 36305907. doi:10.1007/s00259-022-06012-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。